Bayer is unveiling a suite of breakthrough medicines that could reshape treatment for heart failure, cancer and stroke, while leaning on artificial intelligence to speed up drug discovery. Early‑stage gene‑therapy data published in *Nature Medicine* showed that a single infusion improved heart‑function markers in 11 patients over a year with no serious safety signals, and a larger Phase II GenePHIT trial now has more than 170 participants, aiming for results by mid‑2027. In oncology, Bayer’s HER2‑mutated lung‑cancer drug Seviterib achieved 67‑75% response rates in the SOHO‑01 study, earning approvals in the US, Japan and breakthrough status in China. For prostate cancer, the company’s darolutamide, which crosses the blood‑brain barrier minimally, is approved for multiple disease stages and has shown consistent efficacy in Chinese cohorts. A novel oral clot‑blocking agent, Asundexian, cut repeat stroke risk by 26% in a global Phase III trial without raising bleeding, and is now under priority review in China. Bayer’s targeted‑alpha radiopharmaceutical PSMA‑Trillium delivered a 62‑83% PSA response in early trials, offering a precise attack on advanced prostate tumors. Behind these advances, AI tools are redesigning proteins, humanising antibodies and sifting billions of compounds, cutting development cycles from years to weeks. Together, these innovations signal a new era of one‑time treatments and faster, smarter drug pipelines, with China emerging as a pivotal market for rapid approvals.
Read more